Search Results - "Fudio, Salvador"

Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer by Fernández-Teruel, Carlos, Fudio, Salvador, Lubomirov, Rubin

“…Purpose These exposure–response (E–R) analyses integrated lurbinectedin effects on key efficacy and safety variables in relapsed SCLC to determine the adequacy…”
Get full text

Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS by King, Nicholas, Garcia-Martinez, Soledad, Alcaraz, Eider, Grisalena, Alba, Lubomirov, Rubin, Altares, Raquel, Fernandez-Teruel, Carlos, Francesch, Andrés M, Avilés, Pablo M, Fudio, Salvador

“…Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methods to quantify total lurbinectedin, its plasma protein binding to derive the…”
Get full text

A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors by Metaxas, Yannis, Kahatt, Carmen, Alfaro, Vicente, Fudio, Salvador, Zeaiter, Ali, Plummer, Ruth, Sessa, Cristiana, Von Moos, Roger, Forster, Martin, Stathis, Anastasios

“…Summary Background In vitro / in vivo data showed synergism of cisplatin and lurbinectedin in ovarian cancer cells and grafts. This phase I trial investigated…”
Get full text

Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study by Moreno, Irene, Hernández, Tatiana, Calvo, Emiliano, Fudio, Salvador, Kahatt, Carmen, Martínez, Sara, Iglesias, Jorge Luis, Calafati, Román Octavio, Pérez-Ramos, Laura, Montilla, Lola, Zeaiter, Ali, Lubomirov, Rubin

“…This open-label, two-part, phase Ib drug-drug interaction study investigated whether the pharmacokinetic (PK) and safety profiles of lurbinectedin (LRB), a…”
Get full text

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study by Fudio, Salvador, Pérez-Ramos, Laura, Asín-Prieto, Eduardo, Zeaiter, Ali, Lubomirov, Rubin

“…Lurbinectedin is a selective inhibitor of oncogenic transcription U.S. Food and Drug Administration (FDA)-approved for patients with relapsed small cell lung…”
Get full text

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis by Fudio, Salvador, Tabernero, Josep, Subbiah, Vivek, Chawla, Sant P., Moreno, Victor, Longo, Federico, Lopez, Rafael, Anton, Antonio, Trigo, Jose Manuel, Shapiro, Geoffrey, Jeong, Woondong, Villalobos, Victor Manuel, Lubomirov, Rubin, Fernandez-Teruel, Carlos, Alfaro, Vicente, Boni, Valentina

“…Purpose This study assessed the effect of lurbinectedin, a highly selective inhibitor of oncogenic transcription, on the change from baseline in Fridericia’s…”
Get full text

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study by Moreno, Irene, Hernández, Tatiana, Calvo, Emiliano, Fudio, Salvador, Kahatt, Carmen, Fernández, Cristian, Iglesias, Jorge Luis, Corral, Gema, Pérez-Ramos, Laura, Montilla, Lola, Zeaiter, Ali, Lubomirov, Rubin

“…This open-label, two-way, crossover, phase Ib drug-drug interaction study investigated whether the pharmacokinetics (PKs) and safety profile of lurbinectedin…”
Get full text

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma by Mateos, María Victoria, Prosper, Felipe, Martin Sánchez, Jesús, Ocio, Enrique M., Oriol, Albert, Motlló, Cristina, Michot, Jean‐Marie, Jarque, Isidro, Iglesias, Rebeca, Solé, María, Martínez, Sara, Kahatt, Carmen, Fudio, Salvador, Corral, Gema, Zeaiter, Ali, Montilla, Lola, Ribrag, Vincent

“…Previous studies showed antitumor activity for plitidepsin plus dexamethasone (DXM) in relapsed/refractory multiple myeloma (r/r MM), and in vitro synergism…”
Get full text

Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram by Fudio, Salvador, Borobia, Alberto M., Piñana, Enrique, Ramírez, Elena, Tabarés, Beatriz, Guerra, Pedro, Carcas, Antonio, Frías, Jesús

“…We investigate the impact of sex and genotype on citalopram disposition in 35 healthy volunteers who received an oral dose of 20 mg citalopram within a…”
Get full text

Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer by Fernandez-Teruel, Carlos, Gonzalez, Ignacio, Trocóniz, Iñaki F., Lubomirov, Rubin, Soto, Arturo, Fudio, Salvador

“…Background and Objectives Lurbinectedin is an inhibitor of RNA polymerase II currently under clinical development for intravenous administration as a single…”
Get full text

Population Pharmacokinetic‐Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin by Fernández‐Teruel, Carlos, Lubomirov, Rubin, Fudio, Salvador

“…Lurbinectedin is a selective inhibitor of oncogenic transcription. Reversible myelosuppression is its most relevant toxicity. Pharmacokinetic‐pharmacodynamic…”
Get full text

Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics by Fudio, Salvador, Sellers, Alvaro, Pérez Ramos, Laura, Gil-Alberdi, Beatriz, Zeaiter, Ali, Urroz, Mikel, Carcas, Antonio, Lubomirov, Rubin

“…During the last decade, the treatment for many cancer indications has evolved due to intensive clinical research into anti-tumor agents’ combination. In most…”
Get full text

A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors by Ghalib, Mohammad H, Pulla, Mariano Provencio, De Miguel Luken, Maria J, de Juan, Virginia Calvo, Chaudhary, Imran, Hammami, M Bakri, Vikash, Sindhu, Maitra, Radhashree, Martinez, Sara, Kahatt, Carmen, Extremera, Sonia, Fudio, Salvador, Goel, Sanjay

“…Plocabulin (Plo) induces depolymerization of tubulin fibers with disorganization and fragmentation of the microtubule network leading to mitosis. Plo combined…”
Get full text

First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors by Elez, Elena, Gomez-Roca, Carlos, Soto Matos-Pita, Arturo, Argiles, Guillem, Valentin, Thibaud, Coronado, Cinthya, Iglesias, Jorge, Macarulla, Teresa, Betrian, Sarah, Fudio, Salvador, Zaragoza, Katrin, Tabernero, Josep, Delord, Jean-Pierre

“…Summary Background Plocabulin (PM060184) is a novel marine-derived microtubule inhibitor that acts as an antitumor agent. This first-in-human study evaluated…”
Get full text

First-in-human study of PM14 in patients with advanced solid tumors by Vieito, Maria, Ponce Aix, Santiago, Paz-Ares, Luis G., Bahleda, Rastilav, Massard, Christophe, Agreda, Leyre, Banus, Eva, Fernandez, Cristian Marcelo, Cristoveanu, Elena Y, Corral, Gema, Llanero, Lourdes, Lubomirov, Rubin, Kahatt, Carmen Maria, Fudio, Salvador, Nieto, Antonio, Cullell-Young, Martin, Zeaiter, Ali Hassan, Oberoi, Honey Kumar, Garralda, Elena

“…Abstract only 3078 Background: PM14 is a new chemical entity that forms DNA adducts which specifically inhibit RNA synthesis and block active transcription of…”
Get full text

Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC–MS/MS by Nicholas King, Soledad Garcia-Martinez, Eider Alcaraz, Alba Grisalena, Rubin Lubomirov, Raquel Altares, Carlos Fernandez-Teruel, Andrés M. Francesch, Pablo M. Avilés, Salvador Fudio

“…Aims Ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) methods to quantify total lurbinectedin, its plasma protein binding to…”
Get full text

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19 by Varona, Jose F, Landete, Pedro, Lopez-Martin, Jose A, Estrada, Vicente, Paredes, Roger, Guisado-Vasco, Pablo, Fernandez de Orueta, Lucia, Torralba, Miguel, Fortun, Jesus, Vates, Roberto, Barberan, Jose, Clotet, Bonaventura, Ancochea, Julio, Carnevali, Daniel, Cabello, Noemi, Porras, Lourdes, Gijon, Paloma, Monereo, Alfonso, Abad, Daniel, Zuñiga, Sonia, Sola, Isabel, Rodon, Jordi, Vergara-Alert, Julia, Izquierdo-Useros, Nuria, Fudio, Salvador, Pontes, Maria Jose, de Rivas, Beatriz, Giron de Velasco, Patricia, Nieto, Antonio, Gomez, Javier, Aviles, Pablo, Lubomirov, Rubin, Belgrano, Alvaro, Sopesen, Belen, White, Kris M, Rosales, Romel, Yildiz, Soner, Reuschl, Ann-Kathrin, Thorne, Lucy G, Jolly, Clare, Towers, Greg J, Zuliani-Alvarez, Lorena, Bouhaddou, Mehdi, Obernier, Kirsten, McGovern, Briana L, Rodriguez, M Luis, Enjuanes, Luis, Fernandez-Sousa, Jose M, Krogan, Nevan J, Jimeno, Jose M, Garcia-Sastre, Adolfo

“…Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation…”
Get full text

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas by Aspeslagh, Sandrine, Stein, Mark, Bahleda, Rastilav, Hollebecque, Antoine, Salles, Gilles, Gyan, Emmanuel, Fudio, Salvador, Extremera, Sonia, Alfaro, Vicente, Soto-Matos, Arturo, Soria, Jean-Charles

“…This phase I trial evaluated the combination of the marine-derived cyclodepsipeptide plitidepsin (trade name Aplidin) with sorafenib or gemcitabine in advanced…”
Get full text

Valproate-meropenem co-administration, an example of information shortcomings in relevant drug interactions by Borobia, Alberto M, Fudio, Salvador, Carcas Sansuán, Antonio J

Get more information

Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital by Ramirez, Elena, Lei, Su H, Borobia, Alberto M, Piñana, Enrique, Fudio, Salvador, Muñoz, Raúl, Campos, Armando, Carcas, Antonio J, Frias, Jesus

“…The first generic PPI was introduced in Spain in 2001, and since then their prescriptions have increased steadily by about 200%. To evaluate the frequency of…”
Get more information